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Abstract
Introduction: Mer and Tyro3 are receptor tyrosine kinases important for the phagocytosis of apoptotic cells.
Together with Axl, they constitute the TAM receptor family. These receptors can be shed from the cell membrane
and their soluble extracellular regions can be found in plasma. The objective of this study was to elucidate
whether the plasma levels of soluble Mer (sMer) and Tyro3 (sTyro3) were increased in systemic lupus erythematosis
(SLE), rheumatoid arthritis (RA), or critical limb ischemia (CLI).
Methods: ELISA kits were used to test plasma concentrations in controls and in patients with SLE, RA or CLI.
Results: Increased levels of, in particular, sMer and, to some extent, sTyro3, were found in patients with SLE or RA,
but not in patients with CLI. Patients with SLE demonstrated the highest sMer levels and there was a strong
correlation to higher SLE disease activity score (SLEDAI). In contrast, in patients with RA, the sMer levels did not
correlate with the disease activity score (DAS). In SLE, sMer levels were particularly high in those with lupus
nephritis, patients who also had decreased C1q levels and increased titers of anti-DNA antibodies. After therapy,
the plasma concentrations of sMer decreased in parallel to the decrease in SLEDAI score.
Conclusions: The plasma concentrations of sMer and sTyro3 were significantly increased in patients with active
SLE and RA, suggesting the TAM receptor shedding was affected by these autoimmune diseases. In particular, sMer
was increased in SLE, the plasma levels of sMer reflecting disease activity.
Introduction
Mer is a cell membrane-bound receptor tyrosine kinase
(RTK), which together with Axl and Tyro3 constitutes the
TAM receptor family [1,2]. The vitamin K-dependent pro-
teins Gas6 (a ‘product of growth arrest-specific gene 6’)
and protein S are important biological ligands for the
TAM receptors [3]. Axl is ubiquitously expressed, whereas
Tyro3 is predominantly found in the central nervous sys-
tem and the reproductive system. Mer is named after its
expression in monocytes, epithelium and reproductive tis-
sue. Activation of the TAM receptors has been shown to
affect a diversity of cellular functions, including survival,
proliferation, migration and phagocytosis [4]. Mer is an
important mediator of apoptotic cell phagocytosis [5]. It is
also important for phagocytosis of photoreceptor outer
segments (POS) by retinal pigment epithelial (RPE) cells
and genetic defects of the Mer gene Mertk are associated
with retinitis pigmentosa, which results in the develop-
ment of blindness [6].
Recent studies have revealed that the TAM receptors
have pivotal roles in regulation of innate immunity as
regulators of cytokine production in macrophages and
dendritic cells [2,7,8]. The TAM receptors also stimulate
maturation of natural killer cells. Each of these phenom-
ena depends on cooperative interactions between the
TAM receptors and cytokine receptor signaling systems
[2]. The importance of the involvement of the TAM
receptors in regulation of immunity has been clearly
demonstrated in animal models. Thus, mice with triple
knockout of the TAM receptors were found to develop
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severe autoimmune diseases [2]. A milder form of auto-
immunity associated with impaired clearance of infused
apoptotic cells affected Mer knockout mice. These mice
developed progressive lupus-like autoimmunity, with
antibodies to chromatin, DNA, and IgG [9].
The TAM receptors are membrane proteins with mul-
tiple domains. Two Ig-like and two fibronectin-type III
domains constitute the extra-cellular part, which can be
proteolytically shed from the cells. A soluble form of the
Mer (sMer) receptor tyrosine kinase, comprising the
extra-cellular domains, has been found in plasma and
shown to inhibit macrophage clearance of apoptotic cells
and platelet aggregation [10]. Soluble forms of both Axl
and Tyro3 are also present in plasma, at low (subnano-
molar) concentrations. The ligand Gas6, which is
expressed by many cells, but not much in the liver, is also
present at low concentrations in plasma and recently we
demonstrated that Gas6 is circulating in complex with
sAxl [11]. The plasma concentrations of both Gas6 and
sAxl increase in response to acute phase reactions [12].
We have recently found that the plasma concentrations
of Gas6 and sAxl correlate to the inflammatory process
in systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) even though both Gas6 and sAxl in most
of the patients were within the normal range [13].
Systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) are autoimmune diseases of unknown etiol-
ogy [14,15]. SLE patients develop autoantibodies directed
against nuclear elements. These autoantibodies form
immune complexes that contribute to the disease process.
Deposition of these immune deposits in the kidneys initi-
ates an inflammatory response by activating the comple-
ment cascade and recruiting inflammatory cells, and the
resulting lupus nephritis is a severe complication in SLE.
The possible involvement of the Mer and Tyro3 recep-
tors in human autoimmune diseases has not previously
been investigated. In the present study, we have investi-
gated the plasma levels of sMer and sTyro3 in patients
with SLE and RA. In addition, we have investigated
patients with critical limb ischemia (CLI) as a model dis-
ease of non-autoimmune inflammation, because the
pathogenesis of CLI does not involve any autoimmune
component. CLI is caused by severe atherosclerosis and
the inflammatory response is caused by the ischemic tis-
sue damage [16,17]. We now wish to report that sMer is
increased in active SLE and to a lesser extent in RA. In
contrast, neither sMer nor Tyro3 plasma concentrations
are increased in CLI suggesting that the increased sMer
in SLE is not the result of the acute phase response.
Materials and methods
Patients and controls
Patients with SLE (n = 96, 11 men and 85 women) ful-
filling four or more ACR classification criteria for SLE
[18] were recruited at the Department of Rheumatology,
Lund University Hospital, Sweden. The mean age at SLE
diagnosis was 35 years and the mean disease duration at
the time of the study was 10 years. The disease activity
was evaluated using SLEDAI-2K (patients having a
mean SLEDAI score of 8.7) and the evaluation time
points were selected with the objective of including a
wide range of manifestations and SLEDAI scores. As a
consequence, the study also included patients without
evidence of active disease. The study was approved by
the regional ethics board.
Patients with early RA (n = 183, 68 men and 115
women) fulfilling the 1958 ARA criteria of definite RA
were recruited at the Department of Rheumatology, Lund
University Hospital, Sweden between 1985 and 1989. All
consecutive patients that were 18 years or older and with
symptom duration of less than two years were included.
The mean age at diagnosis was 51 years and the mean
duration of symptoms was 11 months. The patients were
evaluated clinically at least yearly and radiographs of
hands and feet were obtained in years 0 to 5 and year 10.
The radiographs were evaluated for joint damage accord-
ing to the Larsen scoring system [19,20]. Analyses of sMer
and sTyro3 were performed on plasma samples retrieved
within six months of inclusion in the prospective early RA
study. The study was approved by the regional ethics
board.
Consecutive patients with CLI (n = 189) were recruited
at the Vascular Centre at Skåne University Hospital,
Malmö, Sweden during a 14-month period. This is the
referral centre for patients with CLI for 700,000 inhabi-
tants in southern Sweden. The diagnosis of CLI was
made according to the Transatlantic Intersociety Consen-
sus (TASC) criteria of ulceration, gangrene or rest pain
caused by peripheral artery disease. The characteristics of
the patient cohort have been described before [21,22].
The 204 control individuals were drawn from the general
population as part of a large prospective study of cardio-
vascular risk factors and alcohol abuse; none of them had
symptomatic CLI, cardiovascular disease, autoimmune
diseases or atherosclerosis. The ethics committee at Lund
University approved the study and all the patients gave
written consent to participate in the study.
ELISA
The sandwich ELISA kits for sMer (DYC891) or sTyro 3
(DYC5600) were obtained from R&D Systems (Minnea-
polis, MN, USA). Maxisorp plates (NUNC A/S, Roskilde,
Denmark) were coated with the monoclonal antibodies
to either hMer or hTyro 3. The plates were blocked with
3% Fish gelatin in 50 mM Tris, 150 mM NaCl, pH 7.4
containing 0.1% Tween 20. The plates were washed five
times with phosphate buffered saline (PBS) (137 mM
NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 0.1% Tween 20,
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pH 7.3, 0.2 um filtered) between every step. The EDTA
plasma samples were diluted 10 times in the blocking
buffer and applied to the plates. The standard curve was
made by serial dilution of recombinant protein and nega-
tive controls were buffer alone. Biotinylated anti-hMer or
anti-hTyro3 antibodies were used for detection together
with ABC/HRP complexes according to the manufac-
turer’s instructions. The plates were developed with orto-
phenylenediamine and hydrogen peroxide and the color
reaction was stopped by the addition of 100 ul 1 M sul-
phuric acid. The absorbance was determined in an auto-
mated plate reader at 490 nm. The sMer and sTyro3
ELISAs were not influenced by the presence of autoanti-
bodies such as rheumatoid factor of either IgG, IgM, or
IgA class.
Statistical analyses
Graphpad 4.0 (Graphpad Software, La Jolla, CA, US)
was used for all statistical analysis. Correlations were
evaluated with Spearman’s rank correlation test. Com-
parisons between groups were performed using the
Mann-Whitney U test. A P < 0.05 was considered signif-
icant for all tests.
Results
The concentrations of sMer and sTyro3 in controls, as
well as in patients, demonstrated skewed distributions
(Figure 1). In controls, the median concentration of
sMer was 17.8 ng/ml and the range was wide (7.9 to
68.3 ng/ml). There were significantly higher concentra-
tions of sMer both in patients with SLE (median 35.6
ng/ml, range 12.to 101.7; P < 0.0001) and in those with
RA (median 20.3 ng/ml, range 7.0 to 94.7; P = 0.0236),
as compared to controls. In particular, the SLE patients
demonstrated increased concentrations of sMer, whereas
only a sub-group of RA patients demonstrated increased
sMer. Patients with CLI demonstrated very similar con-
centrations and distribution of sMer to controls.
The sTyr3 concentrations were significantly different
between controls (median 3.3 ng/ml, range 1.2 to 34.3)
and patients with SLE (median 5.84 ng/ml, range1.61 to
71.79), RA (median 4.3 ng/ml, range 2.5 to 82.5) and
CLI (median 4.2 ng/ml, range 1.8 to 89) (Figure 1). The
sMer and sTyro3 concentrations correlated strongly in
all the groups (Figure 2), the Spearman’s correlation
coefficients were 0.6828 (P < 0.0001), 0.648 (P <
0.0001), 0.5739 (P < 0.001), and 0.3642 (P = 0.079) for
control-, CLI-, RA-, and SLE-groups, respectively.
In patients with SLE, the concentrations of sMer
demonstrated a weak but significant correlation to the
SLEDAI score, (r = 0.25, P = 0.0083) (Figure 3). The
sMer concentrations in patients (n = 24) with a high SLE-
DAI score (≥ 10) were significantly (P = 0.005) higher
(45.1 ng/ml, range 16.4 to 110.3) than in those with a low
SLEDAI score (< 10) (n = 53; 33.0 ng/ml, range 17.4 to
92.8) (Figure 3). The SLEDAI score is composed of many
parameters and we, therefore, tested the sMer concentra-
tions against the individual parameters of the SLEDAI
score. We found that sMer was particularly correlated to
the presence of nephritis (Figure 3). Thus, the patients
with nephritis (n = 16) had higher sMer (n = 16; median
50.9 ng/ml, range 33.8 to 110.3) than those without
nephritis (n = 61; median 32.6 ng/ml, range 16.4 to 92.8),
P < 0.0001. This was not caused by decreased glomerular
filtration as the sMer levels did not correlate to the
serum-creatinine levels.
The concentrations of sMer were also found to corre-
late to decreasing levels of C1q and the presence of anti-
DNA antibodies but not to the presence of rheumatoid
factor of IgG, IgM, or IgA class and patients with rheu-
matoid factor had the same mean sMer and sTyro levels
as those without rheumatoid factor. This observation was
Figure 1 sMer and sTyro3 in patients with CLI, RA, or SLE. The concentrations of sMer and sTyro3 were measured using ELISAs and the
results were plotted on logarithmic scale (Ln scale). Significances are indicated with the asterisks.
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important because it demonstrated that circulating auto-
antibodies against immunoglobulins did not disturb the
ELISA assays. The correlation between sMer and C1q
was negative, r = -0.47, P = 0.020 and as expected the
nephritis group had significantly (P < 0.0001) lower C1q
(n = 24; median 60.5%, 0 to 158%) than those without
nephritis, (n = 72; C1q median 104.5%, 0 to 200%)
(Figure 4).
The anti-DNA positive SLE patients had higher con-
centrations of sMer than the negative group; in the
positive group (n = 22) the median sMer was 45.1 ng/
ml (range 27.5 to 110.3) versus 34.3 ng/ml (range 16.4
to 92.8) in the negative group (n = 55), (P = 0.008)
(Figure 3). As expected, there was also a much higher
percentage of positivity for anti-DNA antibodies in the
nephritis group (70.8%) than in those without nephritis
(19.4%).
In 45 SLE patients with high SLEDAI (12.0 ± 7.7),
samples were also available from time points with low
SLEDAI scores (1.9 ± 3.0) (Figure 5); the corresponding
concentrations of sMer being 39.9 ng/ml (range 17.40 to
110.3, n = 33) and 28.7 ng/ml (range 14.7 to 64.4, n =
34), P = 0.044, respectively. In contrast, the concentra-
tions of C1q were lower at the time of the higher SLE-
DAI score, median value 89% (range 0 to 158%, n = 45)
vs. median value 102% (range 38 to 169%, n = 44), P =
0.0395, respectively.
In contrast to sMer, the concentrations of sTyro3 were
not related to activity parameters like SLEDAI, low C1q
or the presence of nephritis.
Although the concentrations of both sMer and sTyro
were higher in RA than in controls, there were no corre-
lations to disease parameters such as disease activity as
measured by the disease activity score (DAS), the pre-
sence and level of rheumatoid factors of IgA, IgM, or IgG
class or anti-cyclic citrullinated peptide antibodies (anti-
CCP), or elevation of blood sedimentation rate. Further-
more, there were no correlations between sMer or sTyro
Figure 2 Correlations between sMer and sTyro3 in the study groups.
Wu et al. Arthritis Research & Therapy 2011, 13:R62
http://arthritis-research.com/content/13/2/R62
Page 4 of 9
and radiographic changes in hands and feet determined
by the Larsen score at years 0 to 5 and at the 10-year fol-
low-up.
Discussion
SLE is a chronic autoimmune disease characterized by a
plethora of clinical symptoms affecting multiple organs.
Patients with SLE have a high tendency to develop autoan-
tibodies against nuclear components. A defective clearance
of apoptotic cells is believed to be one of multiple causes
of SLE and apoptotic cells are present in the lymph nodes
of these patients [23-26]. In addition, isolated macro-
phages from SLE patients demonstrate reduced ability to
phagocytose apoptotic cells [27]. With this background, it
is noteworthy that we now demonstrate that patients with
SLE have increased concentrations in plasma of sMer, as
Mer is an important receptor for phagocytosis of apoptotic
cells [28].
Figure 3 Correlation between sMer and disease activity in SLE. sMer concentrations in SLE patients correlate to SLEDAI and are different
between patients with or without nephritis and in patients with or without anti-DNA antibodies.
Figure 4 Negative correlation between sMer and C1q concentrations in SLE patients.
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The Mer receptor is expressed in macrophages and den-
dritic cells and is important both for the phagocytosis of
the apoptotic cell and also for regulation of the cytokine
production of these cells [7,29]. Under normal conditions,
the two vitamin K-dependent proteins Gas6 and protein S
bind to the negatively charged phospholipid phosphatidyl-
serine that is exposed as part of the apoptotic process.
Gas6 and protein S bound to the apoptotic cell surface
interact with, and activate, the Mer receptors that are pre-
sent on the macrophages/dendritic cells. This results in
intracellular signaling events, rearrangement of cytoskele-
ton and engulfment of the apoptotic cell [30,31]. The pro-
cess requires that the Mer is an intact membrane-
spanning protein and depends on activation of the intra-
cellular kinase domain of Mer. The presence of fluid phase
sMer in the extra-cellular space can compete with cell
bound Mer acting as a decoy receptor and, thereby, result
in defective phagocytosis [10]. Defective phagocytosis
could potentially also be due to increased shedding of Mer
receptors from the monocyte/macrophage surface result-
ing in decreased surface expression of Mer. Whether any
of these mechanisms are involved in the defective phago-
cytic process in SLE remains to be determined.
Normal phagocytosis of apoptotic cells is not asso-
ciated with inflammation, which is believed to be, at
least partly, due to a shift of cytokine production in the
phagocytes from pro-inflammatory cytokines to cyto-
kines that are anti-inflammatory [23,32]. Mer is also
required for development of B- [33] and T-cell [34,35]
tolerance, which is associated with normal phagocytosis
of apoptotic cells. The defective clearance of apoptotic
cells in SLE contributes to continuous exposure to auto-
antigens and type-I interferon-1 production by the den-
dritic cells, which enhance the inflammatory process,
the production of autoimmune antibodies and formation
of immune-complexes [36,37].
The mechanism through which the plasma concentra-
tion of sMer increases in plasma is not clear. Possibly,
continuous stimulation by apoptotic debris of the
macrophage pool in the SLE patients results in increased
Mer expression and shedding. Apoptotic cells have been
shown to activate Liver X receptor, which induces
expression of Mer [38]. The inflammatory process may
also contribute with increased concentrations of metal-
loproteinases such as tumor necrosis factor alpha-con-
verting enzyme metalloproteinase, which would increase
the proteolytic cleavage of the extra-cellular domain of
Mer. Cleavage of Mer has also been shown to be
enhanced by cell-activating substances such as lipopoly-
saccharide and phorbol myristate acetate [10].
Figure 5 Parallel changes in SLEDAI, sMer and C1q related to disease activity. The SLEDAI and sMer concentrations decrease, whereas the
C1q levels increase after therapy.
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Although the pathogenesis of SLE has a genetic com-
ponent, genome wide association studies have not
resulted in the identification of predisposing genetic
changes [39]. Genetic defects in the MERTK gene,
demonstrated in humans and in the Royal College of
Surgeons (RCS) rat strain, are known to result in defec-
tive phagocytosis by the retinal epithelium of the outer
membrane of photoreceptors [6]. This causes retinitis
pigmentosa, which eventually leads to blindness in the
affected individual [40,41]. However, there are no
reports suggesting that genetic defects in the MERTK
gene increase the risk of SLE in humans. The situation
is different in mice where a genetically modified Mer
receptor (a kinase dead receptor) is demonstrated to
develop SLE-like disease [9]. Moreover, the high ten-
dency to develop autoimmune disease in mice lacking
the Mer receptor demonstrates the importance of the
Mer receptor for regulation of the immune system in
association with the apoptotic process.
The pathogenesis of RA has not been associated with
defective phagocytosis of apoptotic cells and it is note-
worthy that the plasma levels of sMer did not correlate
with disease activity [15]. Moreover, in most of the
patients, the plasma concentrations of sMer were within
the normal range, whereas only very few of the SLE
patients had normal sMer levels. This suggests that the
sMer concentrations do not reflect the inflammatory
process of RA but possibly is related to defective engulf-
ment of apoptotic cells in a subgroup of patients. This
conclusion gains further support from the observation
that patients with CLI, many of which suffer from severe
inflammation, do not have increased plasma levels of
sMer. These results stand in contrast to those obtained
for Gas6 and sAxl. In many different clinical conditions,
including sepsis, CLI and SLE, the concentrations of
Gas6 and sAxl demonstrate strong correlation to inflam-
matory markers suggesting that both Gas6 and Axl
expression increases as part of the acute inflammatory
response [12,13,42].
The plasma concentrations of sMer were found to cor-
relate with the SLEDAI score in SLE patients suggesting
that the sMer concentrations reflect disease activity
rather than disease severity. In particular, those patients
having nephritis demonstrated increased sMer concen-
trations, which was not due to decreased clearance as
there was no correlation between sMer and creatinin in
serum. As expected, the nephritis patients also demon-
strated DNA antibodies, decreased concentrations of C1q
and a negative correlation between sMer and C1q con-
centrations. The DNA-containing immune-complexes
deposit in the glomerular membrane, which binds C1q
and activates a complement thus provoking inflammation
and damage to the membrane barrier of the kidney [43].
As demonstrated by immuno-histochemistry of lupus
nephritis patients, apoptotic tubular cells positively corre-
late with mononuclear cell infiltration, which may be
recruited by MCP-1, a chemokine for macrophages. SLE
patients with nephritis have increased concentrations of
MCP-1 in the urine and the MCP-1 concentrations in
the urine correlate strongly with proteinuria, hematuria
and SLEDAI [44]. Nephritis is a severe complication to
SLE and it is crucial to diagnose this complication as
early as possible. Possibly, determination of sMer concen-
tration can be helpful in the evaluation of SLE disease
activity in general and, in particular, ongoing renal
inflammation.
Conclusions
We demonstrate that the plasma concentrations of the
soluble form of the Mer receptor are significantly
increased in patients with active SLE. As Mer is impor-
tant for the phagocytosis of apoptotic cells and regula-
tion of the immune system, the data suggest that
shedding of Mer is an active process in the SLE disease
process and that the levels of sMer reflect disease
activity.
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